Given that κ-OR antagonists (Domi et al., 2018; Jacobson et al., 2020) are in phase II clinical trials for stress-related mood and anxiety disorders, it would be interesting to explore whether these drugs effectively alleviate stress-related pathologies via κ-OR-mediated-autophagy. Here, OPRK1 is linked to anxiety disorder.